Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation

Toxicology

Volumn 276, Issue 2, 2010, Pages 128-134

  Finaurini, Sara ^a   Ronzoni, Luisa ^a   Colancecco, Alessandra ^a   Cattaneo, Alessandra ^a   Cappellini, Maria Domenica ^a   Ward, Stephen A ^b   Taramelli, Donatella ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

CD34+ erythroid cell differentiation; Dihydroartemisinin; Embryotoxicity; Erythro toxicity; Malaria in pregnancy

Indexed keywords

CD34 ANTIGEN; DIHYDROARTEMISININ; GLYCOPHORIN A; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXICITY; ERYTHROBLAST; ERYTHROID CELL; ERYTHROPOIESIS; GENE EXPRESSION; GLOBIN GENE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE TEST; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; ERYTHROID PRECURSOR CELL; FEMALE; FIRST TRIMESTER PREGNANCY; FLOW CYTOMETRY; METABOLISM; POLYMERASE CHAIN REACTION; TIME; TOXICITY;

ANTIGENS, CD34; ANTIMALARIALS; ARTEMISININS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; FEMALE; FLOW CYTOMETRY; HUMANS; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY TRIMESTER, FIRST; TIME FACTORS;

ANIMALIA;

EID: 77956404806     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.07.016     Document Type: Article

References (41)

1. Aerbajinai W., Zhu J., Gao Z., Chin K., Rodgers G.P. Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 2007, 110:2864-2871.
2. Anfosso L., Efferth T., Albini A., Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J. 2006, 6:269-278.
3. Chen L.J., Wang M.Y., Sun W.K., Liu M.Z. Embryotoxicity and teratogenicity studies on artemether in mice, rats and rabbits. Zhongguo yao li xue bao 1984, 5:118-122.
4. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
5. Clark R.L., Arima A., Makori N., Nakata Y., Bernard F., Gristwood W., Harrell A., White T.E., Wier P.J. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res. 2008, 83:418-434.
6. Clark R.L., Lerman S.A., Cox E.M., Gristwood W.E., White T.E. Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count. Birth Defects Res. 2008, 83:397-406.
7. Clark R.L., White T.E.S.A.C., Gaunt I., Winstanley P., Ward S.A. Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res. 2004, 71:380-394.
8. D'Alessandro S., Gelati M., Basilico N., Parati E.A., Haynes R.K., Taramelli D. Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone: implications for embryotoxicity. Toxicology 2007, 241:66-74.
9. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 2005, 8:85-97.
10. Efferth T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Med. 2007, 73:299-309.
11. Fibach E. Techniques for studying stimulation of fetal hemoglobin production in human erythroid cultures. Hemoglobin 1998, 22:445-458.
12. Fibach E., Manor D., Oppenheim A., Rachmilewitz E.A. Proliferation and maturation of human erythroid progenitors in liquid culture. Blood 1989, 73:100-103.
13. Gunsilius E., Gastl G., Petzer A.L. Hematopoietic stem cells. Biomedecine Pharmacotherapie 2001, 55:186-194.
14. Li Q., Weina P.J. Severe embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women. Molecules 2010, 15:40-57.
15. Longo M., Zanoncelli S., Della Torre P., Rosa F., Giusti A., Colombo P., Brughera M., Mazue G., Olliaro P. Investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) using the Frog Embryo Teratogenesis Assay-Xenopus (FETAX). Reprod. Toxicol. 2008, 25:433-441.
16. Longo M., Zanoncelli S., Manera D., Brughera M., Colombo P., Lansen J., Mazue G., Gomes M., Taylor W.R.J., Olliaro P. Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro. Reprod. Toxicol. 2006, 21:83-93.
17. Longo M., Zanoncelli S., Torre P.D., Riflettuto M., Cocco F., Pesenti M., Giusti A., Colombo P., Brughera M., Mazue G., Navaratman V., Gomes M., Olliaro P. In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos. Reprod. Toxicol. 2006, 22:797-810.
18. McGready R., Stepniewska K., Lindegardh N., Ashley E.A., La Y., Singhasivanon P., White N.J., Nosten F. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 2006, 62:1021-1031.
19. McGready R., Stepniewska K., Ward S.A., Cho T., Gilveray G., Looareesuwan S., White N.J., Nosten F. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 2006, 62:367-371.
20. Menendez C., D'Alessandro U., ter Kuile F.O. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect. Dis. 2007, 7:126-135.
21. Mercer A.E. The role of bioactivation in the pharmacology and toxicology of the artemisinin-based antimalarials. Curr. Opin. Drug Discov. Devel. 2009, 12:125-132.
22. Meshnick S.R., Taylor T.E., Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol. Rev. 1996, 60:301-315.
23. Moutouh-de Parseval L.A., Verhelle D., Glezer E., Jensen-Pergakes K., Ferguson G.D., Corral L.G., Morris C.L., Muller G., Brady H., Chan K. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J. Clin. Invest. 2008, 118:248-258.
24. Neildez-Nguyen T.M., Wajcman H., Marden M.C., Bensidhoum M., Moncollin V., Giarratana M.C., Kobari L., Thierry D., Douay L. Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivo. Nat. Biotechnol. 2002, 20:467-472.
25. Nosten F., McGready R., d'Alessandro U., Bonell A., Verhoeff F., Menendez C., Mutabingwa T., Brabin B. Antimalarial drugs in pregnancy: a review. Curr. Drug Saf. 2006, 1:1-15.
26. Palis J. Ontogeny of erythropoiesis. Curr. Opin. Hematol. 2008, 15:155-161.
27. Palis J., Yoder M.C. Yolk-sac hematopoiesis: the first blood cells of mouse and man. Exp. Hematol. 2001, 29:927-936.
28. Parapini S., Basilico N., Mondani M., Olliaro P., Taramelli D., Monti D. Evidence that haem iron in the malaria parasite is not needed for the antimalarial effects of artemisinin. FEBS Lett. 2004, 575:91-94.
29. Ribeiro I.R., Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med. Trop. (Mars) 1998, 58:50-53.
30. Robert A., Dechy-Cabaret O., Cazelles J., Meunier B. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Acc. Chem. Res. 2002, 35:167-174.
31. Ronzoni L., Bonara P., Rusconi D., Frugoni C., Libani I., Cappellini M.D. Erythroid differentiation and maturation from peripheral CD34+ cells in liquid culture: cellular and molecular characterization. Blood Cells Mol. Dis. 2008, 40:148-155.
32. Stocks P.A., Bray P.G., Barton V.E., Al-Helal M., Jones M., Araujo N.C., Gibbons P., Ward S.A., Hughes R.H., Biagini G.A., Davies J., Amewu R., Mercer A.E., Ellis G., O'Neill P.M. Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs. Angew. Chem. Int. Ed. Engl. 2007, 46:6278-6283.
33. Timens W., Kamps W.A. Hemopoiesis in human fetal and embryonic liver. Microsc. Res. Tech. 1997, 39:387-397.
34. Wang J., Huang L., Li J., Fan Q., Long Y., Li Y., Zhou B. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 2010, 5:e9582.
35. Ward S.A., Sevene E.J., Hastings I.M., Nosten F., McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect. Dis. 2007, 7:136-144.
36. White T.E., Bushdid P.B., Ritter S., Laffan S.B., Clark R.L. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res. 2006, 77:413-429.
37. White T.E., Clark R.L. Sensitive periods for developmental toxicity of orally administered artesunate in the rat. Birth Defects Res. 2008, 83:407-417.
38. WHO Assessment of the safety of artemisinin compounds in pregnancy WHO/CDS/MAL/20903.1094 WHO/GMP/TDR/Artemisinin/07.1 2006.
39. WHO Guidelines for the treatment of malaria 2006.
40. WHO Technical Expert Group meeting on intermittent preventive treatment in pregnancy (IPTp) 2007.
41. WHO World malaria report "WHO/HTM/GMP/2008.1" 2008.